# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from...
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data fr...
JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...
Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study dataOngoing...